FDA Brief

Warning letters Biologics

FDA warning letter to

Cryos International USA LLC

High riskIssued Oct 24, 2022Posted Dec 6, 2022Division of Biological Products Operations I

Cryos International USA released and distributed anonymous donor semen without required infectious disease testing and quarantine.

What happened

FDA inspected Cryos International USA's Orlando, Florida facility from February 9 to March 8, 2022 and found significant deviations from the rules for human cells, tissues, and cellular/tissue-based products (HCT/Ps). The agency found that semen from anonymous donors was released and distributed without required West Nile Virus testing/retesting and six-month quarantine, without required retesting for Chlamydia, gonorrhea, syphilis, and CMV, and after incomplete donor screening. FDA said the company's March 22, 2022 corrective-action response was inadequate.

What FDA found

  1. FDA says Cryos failed to test anonymous semen donors for West Nile Virus at the first in-season donation and to retest them at least six months later, and failed to keep the semen quarantined until retesting was complete.

    21 CFR 1271.80(a), 1271.85(d), 1271.60(a)
  2. FDA says Cryos failed to retest anonymous semen donors for Chlamydia trachomatis, Neisseria gonorrhea, Treponema pallidum, and cytomegalovirus at least six months after donation and failed to quarantine the semen until retesting was complete.

    21 CFR 1271.85(d), 1271.60(a)
  3. FDA says Cryos's donor history questionnaires did not ask about all required risk factors for communicable diseases, including recent sex between men, sex for money or drugs, injection drug use, HIV/HBV/HCV exposure, hepatitis contact, vaccinia, military-base residence, and Zika.

    21 CFR 1271.75(a)(1)
  4. FDA says Cryos released semen from repeat anonymous donors without a complete donor screening procedure within the previous six months.

    21 CFR 1271.75(a)
  5. FDA says Cryos's procedures for donor eligibility were incomplete, including missing Chlamydia, France travel, cumulative military timeframe, West Nile Virus retesting, and Zika sexual-contact questions.

    21 CFR 1271.47(a)

What FDA wants

FDA asks Cryos to respond in writing within 15 working days with specific corrective and preventive steps and documentation, and to attend a virtual regulatory meeting within 30 calendar days. FDA also says affected semen from donors with incomplete screening/testing must stay in quarantine unless FDA grants an exemption.

Who should pay attention

  • fertility clinics and sperm banks using donor semen
  • recipients of donor sperm and their clinicians
  • tissue banks and distributors handling human cells or tissues

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk